Biotechnology company Biocon has launched the first anti-CD6 monoclonal antibody, alzumab (Itolizumab), to treat patients with chronic plaque psoriasis in India.
Indicated for the treatment of moderate-to-severe psoriasis, Alzumab is formulated as an infusion drug and is manufactured at Biocon's Biopharma manufacturing facility at Biocon Park in Bangalore, India.
Biocon chairperson and managing director Kiran Mazumdar-Shaw said, "Biocon's ALZUMAb (Itolizumab) is the first anti-CD6 monoclonal antibody to be commercialized, an outcome of path breaking research in India."
Offering superior safety and similar efficacy profile compared to other existing therapies, Alzumab with a unique Mechanism of Action (MOA) has a long remission period with very low opportunistic infection rate.
Biocon president-marketing Rakesh Bamzai added, "Compared to existing therapies, ALZUMAb offers a better safety and efficacy profile to the patients with longer remission periods and lower infection rates that will lead to better patient compliance and overall reduction in the cost burden to the patient."
